Cardiff Oncology, Inc.
CRDF$136M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN DIEGO32 employees
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Nov 15, 2026
35wMarket Overview
Stock performance and key metrics
CRDF News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
FOLFIRI
Metastatic Colorectal Cancer
Onvansertib
Colorectal Cancer
Cytarabine
Acute Myeloid Leukemia
Abiraterone
Metastatic Castration-Resistant Prostate Cancer
Nanoliposomal irinotecan
Pancreatic Ductal Adenocarcinoma
FOLFOX
Metastatic Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FOLFIRI | Phase 2 | Metastatic Colorectal Cancer | - | - |
Onvansertib | Phase 2 | Colorectal Cancer | - | - |
Cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Abiraterone | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
Nanoliposomal irinotecan | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
FOLFOX | Phase 2 | Metastatic Colorectal Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply